| Price | 22.675 on 17-04-2026 at 18:15:00 |
|---|---|
| Change | -0.15 -0.66% |
| Buy | 23.80 |
| Sell | 21.55 |
| Last Trade: | Sell 57.00 at 22.45 |
| Day's Volume: | 2,422 |
| Last Close: | 22.675 |
| Open: | 22.925 |
| ISIN: | SE0015244520 |
| Day's Range | 21.80 - 22.925 |
| 52wk Range: | 20.45 - 41.40 |
| Market Capitalisation: | - |
| VWAP: | 22.80317 |
| Shares in Issue: | 65.80m |
Bioinvent Inter (0H22) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 57 | 22.45 | SI Trade |
16:18:49 - 17-Apr-26 |
| Sell* | 109 | 22.425 | SI Trade |
15:51:34 - 17-Apr-26 |
| Sell* | 118 | 22.525 | SI Trade |
14:28:29 - 17-Apr-26 |
| Buy* | 119 | 22.50 | SI Trade |
13:32:28 - 17-Apr-26 |
| Buy* | 145 | 22.45 | SI Trade |
13:10:49 - 17-Apr-26 |
| Buy* | 937 | 22.90 | SI Trade |
10:03:20 - 17-Apr-26 |
| Buy* | 937 | 22.90 | SI Trade |
10:03:20 - 17-Apr-26 |
| Sell* | 164 | 22.80 | SI Trade |
15:56:44 - 16-Apr-26 |
| Sell* | 10,000 | 22.45 | SI Trade |
10:32:13 - 16-Apr-26 |
| Sell* | 10,000 | 22.45 | SI Trade |
10:32:13 - 16-Apr-26 |
Bioinvent Inter (0H22) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 31st Mar 2026 9:45 am | MFN | BioInvent International AB publishes Annual Report 2025 |
| 24th Mar 2026 7:00 am | MFN | Notice to Annual General Meeting in BioInvent International AB |
| 26th Feb 2026 7:00 am | MFN | BioInvent International AB: Year-end report January 1 - December 31, 2025 |
| 5th Jan 2026 6:30 am | MFN | BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer |
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |
